Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06397846

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.

Led by Centre Hospitalier Universitaire de Besancon · Updated on 2026-03-16

100

Participants Needed

2

Research Sites

128 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The challenge for medical oncology is to develop plasma biomarkers that can detect the influence of the stroma on diagnosis, prognosis and response to chemotherapy. Today, there is no validated blood test to help diagnose pancreatic cancer (PDAC). The search for blood biomarkers of the tumor stroma and immunological markers is therefore a major challenge in orienting the diagnosis towards PDAC and optimizing the therapeutic management of pancreatic cancers. The aim of the study is to identify biomarkers associated with the presence of malignant pancreatic lesions (patients from the Pancreas-CGE cohort, a cohort already set up by our team) compared with benign lesions (patients followed up for benign pancreatic lesions). Candidate biomarkers from our preliminary work will be considered initially. Other biomarkers may be explored secondarily. The ultimate goal is to develop a clinico-biological signature that is as efficient as possible in predicting the presence of malignant pancreatic lesions compared with benign ones.

CONDITIONS

Official Title

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 18 years or older
  • Patients followed for benign pancreatic lesions, including chronic pancreatitis or acute pancreatitis more than 4 weeks ago
  • Indication for echo-endoscopy due to suspected precancerous pancreatic lesions or cystic lesions such as serous cystadenomas
Not Eligible

You will not qualify if you...

  • Diagnosis of malignant pancreatic tumor
  • Legal incapacity or limited legal capacity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University Hospital of Besancon

Besançon, France

Actively Recruiting

2

Hôpital Nord Franche-Comté

Montbéliard, France

Actively Recruiting

Loading map...

Research Team

A

Angélique VIENOT, Dr

CONTACT

M

Marion JACQUIN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions. | DecenTrialz